The purpose of the trial is to find out whether adding orelabrutinib to the usual regimen can keep the disease from getting worse for a longer period of time. After a screening visit, participants are randomly assigned to one of the two groups, and neither the participants nor the doctors know which group they are in. Treatment is given in repeated cycles over several months, with regular check‑ups that include blood tests, heart checks, and questionnaires about quality of life. The study follows participants for several years to see how long they stay free of disease progression and to monitor safety.

The purpose of the study is to evaluate how well these treatments work and how safe they are for patients. Participants will receive either Zilovertamab Vedotin alone or together with Nemtabrutinib. Zilovertamab Vedotin is given as an injection into a vein, while Nemtabrutinib is taken as a tablet by mouth. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients.

The study will take place over several weeks, during which participants will be closely monitored by healthcare professionals. They will undergo regular check-ups and tests to assess their response to the treatment and to ensure their safety. The study aims to provide valuable information that could lead to better treatment options for people with these types of blood cancers.

The purpose of the study is to evaluate how well glofitamab works in people whose disease has returned or did not respond well after CAR T-cell therapy. Participants will receive a series of IV infusions over several months, with regular doctor visits and imaging scans to check whether the cancer shrinks or disappears. Terms such as “response” mean a measurable reduction in tumor size, and “complete response” means no detectable cancer remains on the scans. The study will follow each participant for about a year to see how long any benefit lasts and to monitor any side effects.

Participants in the study will receive pirtobrutinib as a single medication. The goal is to determine how long the disease remains stable without getting worse, which is known as progression-free survival. This term refers to the length of time from the start of the medication until the cancer begins to grow again or the patient passes away from any cause.

During the study, the effectiveness of the drug will be monitored by looking at how much the cancer shrinks or disappears, which is called the overall response rate. Researchers will also track how long patients live and how the treatment impacts their daily quality of life. Any side effects or issues that cause a person to stop taking the medication will also be recorded.

The purpose of this research is to determine how effective the combination of glofitamab and pirtobrutinib is in treating patients with Mantle Cell Lymphoma, both in those who have previously received treatment and in those who have never been treated before. The study includes two groups of patients: those whose disease has returned or worsened after previous treatments, and elderly patients who have not yet received any treatment for their condition.

During the study, patients will receive treatment for up to 36 months. The treatment involves regular doses of medication according to a specific schedule. Patients will be monitored throughout the study period to assess how well the treatment is working and to check for any side effects. The study team will track whether the cancer improves, stays the same, or gets worse over time.

The purpose of the study is to see if this combination of pirtobrutinib and rituximab can be a good alternative to the usual treatments for MCL, which often involve a mix of chemotherapy and immunotherapy. The study will follow participants over a period of time to monitor how well the treatment works and to check for any side effects. Participants will receive the treatment and be observed for changes in their condition, with regular assessments to track their progress. The study aims to provide valuable information on whether this new combination can help manage the disease more effectively than current standard treatments.

Throughout the study, researchers will collect data on how the treatment affects the cancer and the overall health of the participants. This includes looking at the rate of complete remission, which means the cancer is no longer detectable, and monitoring any adverse effects that may occur. The study will also evaluate the quality of life of participants using questionnaires designed to measure well-being and daily functioning. By the end of the study, the goal is to have a clearer understanding of the potential benefits and risks of using pirtobrutinib and rituximab together for treating indolent MCL.

The purpose of this study is to assess how well the combination of acalabrutinib and R-CHOP works in treating patients who have not received any previous treatment for their MCL. Participants in the study will take acalabrutinib in the form of film-coated tablets, along with the R-CHOP regimen. The study will monitor the response to the treatment over a period of time to see how effective it is in managing the disease.

Throughout the study, participants will be closely observed to track their response to the treatment and any side effects they may experience. The study aims to provide valuable information on the effectiveness of this treatment combination for individuals with previously untreated mantle cell lymphoma. The trial is expected to continue until the end of 2028, with recruitment starting in mid-2025.

The purpose of the study is to see if the combination of Sonrotoclax and Zanubrutinib works better than the current standard treatment. Participants in the study will be randomly assigned to receive either the new combination or the standard treatment. The study will be conducted in a way that neither the participants nor the researchers know who is receiving which treatment, to ensure unbiased results. The study will monitor how long patients live without their disease getting worse, as well as other health outcomes.

Throughout the study, participants will take the medications orally, meaning they will swallow them. The study will last for a period of time, during which participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to gather information that could lead to better treatment options for people with relapsed or refractory mantle cell lymphoma in the future.

The purpose of this study is to evaluate the safety and effectiveness of this new treatment. Participants will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will monitor how the body responds to the treatment and any side effects that may occur. The trial will also compare the new treatment to existing treatments to see if it offers any advantages.

In addition to HSP-CAR19M, other medications used in the study include Beneflur (containing fludarabine phosphate), Genoxal (containing cyclophosphamide monohydrate), RoActemra (containing tocilizumab), and Levact (containing bendamustine hydrochloride). These medications are used to prepare the body for the new treatment or to manage symptoms. Some participants may receive a placebo, which looks like the treatment but does not contain the active medicine. The study will continue until the end of 2025, with regular check-ups to assess the treatment’s impact on the cancer and the patient’s overall health.

The purpose of the study is to determine how safe and tolerable AZD0486 is when given to patients with these types of blood cancers. The study will also find the best dose to use in future research. Participants will receive the treatment either through an infusion into a vein or an injection under the skin. The study will be conducted in several phases, starting with a smaller group of participants to assess safety, and then expanding to include more participants to further evaluate the treatment’s effectiveness.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The trial aims to provide valuable information on how well AZD0486 works in treating these blood cancers and to ensure that it is safe for patients. The study is expected to continue until 2026, with recruitment starting in 2025.

The purpose of the study is to evaluate how well this combination of medications works in patients whose mantle cell lymphoma has returned or has not responded to previous treatments. The study will involve several cycles of treatment, and the response to the treatment will be assessed at different stages. The study aims to determine the best response rate, which refers to how well the cancer responds to the treatment, either during the middle of the treatment or at the end of the treatment period.

Participants in the study will receive the treatment over a period of time, with regular assessments to monitor their response and any side effects. The study will help to understand the safety and effectiveness of this treatment combination for mantle cell lymphoma. The trial is expected to continue until 2026, providing valuable information on the potential benefits of these medications for patients with this type of cancer.

The purpose of the study is to evaluate how well these treatments work in managing high-risk Mantle-Cell Lymphoma. Participants in the study will receive one of the treatment combinations and will be monitored over a period to see how their disease responds. The study will involve regular visits to the clinic for treatment and check-ups, which may include imaging tests to assess the progress of the disease. The study aims to determine the effectiveness of these treatments in controlling the disease and improving patient outcomes.

Throughout the study, participants will be closely observed for any side effects or changes in their condition. The study will help researchers understand the potential benefits and risks of these treatment combinations for Mantle-Cell Lymphoma. The information gathered from this study could contribute to developing better treatment strategies for this type of cancer in the future.

The study will test a medication called capivasertib (also known as TRUQAP) that comes in the form of film-coated tablets taken by mouth. Patients will receive either 160 mg or 200 mg tablets. This medication works by targeting specific processes that cancer cells use to grow and survive.

The main purpose of this study is to determine how well capivasertib works in treating these types of lymphoma by measuring how many patients show improvement after taking the medication. During the study, doctors will monitor patients’ responses to treatment through various medical examinations and imaging tests. They will also track how long any positive responses to the treatment last and evaluate the medication’s safety.

Participants in this study will continue taking ibrutinib in the form of a hard capsule, which is taken orally. The study will monitor the long-term effects of ibrutinib and any potential side effects that may arise. Patients will be observed for any serious adverse events, which are significant health issues that may occur during the treatment. The study aims to ensure that patients who benefit from ibrutinib can maintain their treatment regimen and continue to manage their condition effectively.

The purpose of the study is to see if adding Venetoclax after the initial treatment with Rituximab, Bendamustine, and Cytarabine can improve the outcomes for patients. The study will follow participants over a period to monitor their response to the treatment. Initially, patients will receive Rituximab, Bendamustine, and Cytarabine through intravenous infusions, which means the medication is given directly into a vein. After this phase, Venetoclax will be taken orally, which means it is swallowed in pill form. The study aims to determine if this combination can help patients live longer without the disease getting worse.

Throughout the study, researchers will observe how well the treatment works and how safe it is for the participants. They will look at how long patients remain free from disease progression, the overall survival rates, and any side effects that may occur. The study will also assess the proportion of patients who achieve complete remission, which means the disappearance of all signs of cancer in response to treatment. This trial is an important step in finding more effective treatments for high-risk elderly patients with Mantle Cell Lymphoma.

The purpose of this study is to evaluate how well the combination of acalabrutinib and rituximab works in elderly patients who have not yet received treatment for their mantle cell lymphoma. Participants in the study will receive these medications and will be monitored over time to see how their disease responds. The study will compare the results to previous data from another trial to understand the effectiveness of this treatment combination.

Throughout the study, participants will be regularly assessed to track their progression-free survival, which means the length of time during and after treatment that the patient lives with the disease without it getting worse. Other aspects such as the complete response rate, overall survival, and safety of the treatment will also be evaluated. The study aims to provide valuable insights into the treatment of mantle cell lymphoma in elderly patients.

Participants in the study will be randomly assigned to one of the two treatment groups. The study will be conducted over a period of time, with regular check-ups and assessments to monitor the progress of the disease and the patient’s response to the treatment. The main focus will be on how long patients can live without the disease getting worse, which is known as progression-free survival. Other aspects such as overall survival, disease response, safety, and quality of life will also be evaluated.

This study is designed to provide valuable information on the best treatment options for older patients with untreated Mantle Cell Lymphoma. By comparing the effectiveness of Rituximab with Ibrutinib against Rituximab with chemotherapy, researchers hope to find a treatment that offers better outcomes for patients. The study will continue until the end of 2026, with the goal of improving the understanding and management of this challenging disease.

The purpose of this study is to evaluate how safe and effective this new treatment is for patients whose cancer has returned or has not responded to previous treatments. The study will be conducted in two phases. In the first phase, researchers will determine the best dose of MB-CART19.1 to use. In the second phase, they will assess how well the treatment works in reducing cancer cells in the body. Throughout the study, participants will receive the treatment and be monitored for any side effects and improvements in their condition.

Participants will receive the MB-CART19.1 treatment through an intravenous infusion, which means it will be delivered directly into the bloodstream. The study aims to find out if this approach can help control or eliminate the cancer, and how long any positive effects might last. The trial will also look at the overall health and survival of participants over time. Some participants may receive a placebo as part of the study to help compare the effects of the treatment. The study is expected to continue until the end of 2025.

The trial will investigate a new medication called Golcadomide (also known by its code name CC-99282), which is taken orally in capsule form. This medication will be tested both on its own and in combination with other treatments for NHL, including Rituximab, Obinutuzumab, Tafasitamab, and Valemetostat Tosylate. Rituximab is a monoclonal antibody, which is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. The purpose of the study is to determine the safety and tolerability of Golcadomide alone and in combination with these other treatments, as well as to find the best dose to use in future studies.

Participants in the study will receive the medication and be monitored for any side effects or changes in their condition. The study will also look at how the body processes the medication and its preliminary effectiveness in treating the disease. The trial is designed to gather important information that could lead to new treatment options for people with relapsed or refractory NHL.

The main goal of the study is to determine the effectiveness of these combination therapies in reducing or eliminating signs of cancer in the blood and bone marrow. This is measured using a technique called droplet digital polymerase chain reaction (ddPCR), which helps detect very small amounts of cancer cells. The study looks specifically at the “minimum residual disease” rate, which means the amount of cancer cells that remain after treatment.

Participants in the study will receive either a combination of Ibrutinib plus a CD20 antibody, such as Rituximab or Obinutuzumab, or a combination of Ibrutinib, Venetoclax, and a CD20 antibody. These treatments are given over six cycles, and researchers will monitor how the cancer responds to these therapies. Some participants may receive a placebo. This trial aims to find the most effective treatment options for reducing cancer in patients with untreated mantle cell lymphoma.

The purpose of the study is to compare the effectiveness of these two treatment combinations. Patients participating in the study will receive one of the two treatment combinations. The study will monitor the patients over a period to see how well the treatments work in controlling the disease. The treatments are administered through infusions, which means they are given directly into the bloodstream through a vein. The study will also look at how long the treatments can keep the disease from getting worse and how they affect the patients’ overall health and quality of life.

Throughout the study, patients will be regularly assessed by healthcare professionals to track their progress and any side effects they may experience. The study aims to provide valuable information on which treatment combination is more effective for patients with Mantle Cell Lymphoma who cannot undergo a stem cell transplant. This information could help guide future treatment decisions for this condition.

The purpose of the study is to evaluate how well Odronextamab works in shrinking tumors and to assess its safety in patients. The study includes several subtypes of B-cell non-Hodgkin lymphoma, such as follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and marginal zone lymphoma. Patients participating in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the patients over a period of time to see how their cancer responds to the treatment and to check for any side effects.

Throughout the study, researchers will collect information on how the cancer responds to Odronextamab and any changes in the patients’ health. This information will help determine the effectiveness of the treatment and its potential as a new option for patients with B-cell non-Hodgkin lymphoma. The study aims to provide valuable insights into the treatment of this type of cancer and improve future care for patients. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

The purpose of the study is to see how well patients with previously treated Mantle Cell Lymphoma respond to pirtobrutinib compared to other BTK inhibitors. Participants in the study will be randomly assigned to receive either pirtobrutinib or a BTK inhibitor chosen by their doctor. The study will monitor the participants over a period of time to see how long they can live without their disease getting worse, which is known as progression-free survival.

During the study, participants will take the medication in the form of tablets, which are taken by mouth. The study will last for up to 48 weeks, and participants will have regular check-ups to monitor their health and the effects of the treatment. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active substance. The study aims to provide valuable information on the best treatment options for patients with Mantle Cell Lymphoma.

Participants in the study will receive the combination of Ibrutinib and Rituximab over a period of time. The study will monitor the participants to see how well the treatment works and to check for any side effects. The goal is to see if this combination can be a good alternative to the usual treatment, which is a type of chemotherapy known as the R-CHOP regimen. The study will look at how many patients have a complete response to the treatment after 12 months.

Throughout the study, researchers will also gather information on the overall response rate, how long patients stay free from disease progression, and the duration of the response to the treatment. They will also assess the quality of life of the participants during the treatment. Additionally, the study will include genomic studies to better understand the disease and the effects of the treatment. The study is expected to continue until the end of 2029.

The purpose of the study is to evaluate how well these treatment combinations work in terms of failure-free survival, which refers to the length of time during and after treatment that a patient lives with the disease without it getting worse. The study will follow participants over a period of time to see how long they remain free from disease progression. Participants will receive one of the treatment combinations and will be monitored regularly to assess their response to the treatment and any side effects they may experience. The study aims to provide valuable information on the effectiveness and safety of these treatment options for patients with Mantle Cell Lymphoma.

Throughout the study, researchers will also look at other important outcomes, such as progression-free survival, which is the time during and after treatment that a patient lives without the disease worsening, and overall survival, which is the time a patient lives from the start of the study. Additionally, the study will assess the quality of life of participants during the treatment period. This research is important for understanding how these treatments can help manage Mantle Cell Lymphoma and improve the lives of those affected by this condition.

The purpose of this study is to provide continued access to these treatments for participants who benefit from them. Participants will be randomly assigned to one of the treatment groups and will receive the medications either as capsules taken by mouth or as injections. The study will monitor the participants’ response to the treatment over a period of time to determine which combination is most effective in managing the disease.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to assess the effectiveness of the treatments. The study aims to find the best treatment option for patients with relapsed or refractory Mantle Cell Lymphoma, providing valuable information that could improve future treatment strategies for this condition.

The purpose of the study is to assess how well Glofitamab works in treating these lymphomas after patients have already received a type of therapy known as CAR T-cell therapy. This therapy involves modifying a patient’s own immune cells to better fight cancer. The study will involve a series of treatments over a period of time, with regular monitoring to see how the cancer responds to the medication. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Participants in the study will receive the treatment through infusions and will be closely monitored by healthcare professionals. The study aims to understand the effectiveness of Glofitamab in improving survival rates and managing the disease. It will also look at how well patients tolerate the treatment and any changes in their quality of life. The study is designed to provide valuable information that could lead to better treatment options for people with these challenging types of lymphoma.

The purpose of the study is to evaluate how well this combination of medications works in treating Mantle Cell Lymphoma. Participants in the study will receive these medications over a period of time, and their health will be monitored closely by the research team. The study will involve several cycles of treatment, and the participants will have regular check-ups to assess their response to the treatment. The goal is to see if the combination can help achieve a state where no cancer cells are detectable, known as MRD-negative complete response.

Throughout the study, participants will be observed for any side effects or changes in their condition. The research team will collect data on how the disease responds to the treatment and how long the response lasts. This information will help determine the potential benefits and risks of using Acalabrutinib, Venetoclax, and Rituximab together for treating Mantle Cell Lymphoma. The study aims to provide valuable insights into improving treatment options for patients with this type of cancer.

The purpose of the study is to evaluate how effective the KTE-X19 therapy is in treating patients who have shown a partial response to Ibrutinib treatment. During the study, patients will first receive Ibrutinib to manage their condition. If they achieve a partial response, they will then receive the KTE-X19 therapy. This involves an infusion, which is a way of delivering the treatment directly into the bloodstream. The study will monitor patients for a period of time to assess the response to the treatment and any potential side effects.

In addition to KTE-X19 and Ibrutinib, the study may also involve other medications such as Cyclophosphamide and Fludarabine, which are chemotherapy agents used to prepare the body for the cell therapy. The trial aims to provide insights into the effectiveness of this combination of treatments in managing Mantle Cell Lymphoma and improving patient outcomes. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the treatment’s impact on their condition.

The purpose of the study is to evaluate the safety and effectiveness of these medications when used in combination. The study is divided into different steps. Initially, the safety of using Obinutuzumab and Ibrutinib together is assessed. If this combination is safe, the study then explores adding Venetoclax to the mix. The final step involves confirming the safety of all three medications used together. Throughout the study, participants will receive these medications in specific doses, and their health will be closely monitored to ensure their safety.

Participants in the study will receive the medications in different forms: Obinutuzumab as a concentrate for infusion, Venetoclax as a tablet, and Ibrutinib as a capsule. The study aims to find the best dose of these medications that can be tolerated by patients while also being effective in treating Mantle Cell Lymphoma. The study will continue until the researchers gather enough information to understand how well these medications work together and how safe they are for patients.